The practical research interest is that amylin signaling reduces food intake through the hindbrain and area postrema a satiety route that is largely independent of incretin (GLP-1/GIP) signaling
Based on my lifestyle and my own personal needs, it has been a tool that's been helpful
In aggregate, they represent a massive share of the global metabolic disease burden, accounting for 38% of the worlds adult population living with obesity (Figure 2)
Everyone is different, and people who have transitioned from semaglutide to retatrutide tend to empathize and swap strategies such as adjusting dose timing, consuming smaller meals, or prioritizing sleep to manage fatigue
These medications are primarily approved for the treatment of type 2 diabetes, but they have also been approved for use in adults with obesity who have a body mass index (BMI) of 30+, or a BMI of 27+ with a minimum of one weight-related medical problem like high blood pressure or high cholesterol
Learn the real benefits, risks, safety concerns, and what clinical research says about low-dose semaglutide and other GLP-1 medications